Skip to main content
. 2019 Sep 11;10(11):2117–2123. doi: 10.1111/1759-7714.13195

Figure 2.

Figure 2

Kaplan‐Meier survival curves showing the overall survival of ALK‐positive NSCLC patients treated with immune checkpoint inhibitors. ALK, anaplastic lymphoma kinase; NSCLC, non‐small‐cell lung cancer; PD‐1, programmed death 1; PD‐L1, programmed death ligand 1.